+ 0.56
+ 0.2%
+ 0.98
+ 0.28%
+ 0.96
+ 0.61%

Avicanna Closes Private Placement With Chinese Pharma Group Tasly

April 21, 2020 7:57 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Versión en Español en El Planteo: Avicanna Cierra Inversión Privada con el Gigante Farmacéutico Tasly

Ontario-based cannabis researcher and producer Avicanna (OTC:AVCNF) announced Tuesday the closing of a private placement deal led by Tasly.

Tasly Holding Group Co., Ltd. is a Chinese pharmaceutical and health care company with a $22-billion market cap. The group is listed on the Shanghai Stock Exchange.

The CA$2.56-million ($1.81 million) deal includes the purchase of 3.2 million units at a price of CA$0.80 per unit. Each unit consists of one Avicanna common share plus one quarter of one common share purchase warrant, exercisable until April 2, 2022, at a price of CA$1.20 per Warrant Share.

Coupled with reduced expenditures and re-focused business model, the funds give Avicanna the runway to execute its business plan, said CEO Aras Azadian. 

Avicanna plans to use the funding for commercialization, corporate development and general working capital purposes. 

“When we initiated the financing, our stock price was depressed and the COVID-19 pandemic was making it difficult for all companies to raise money. However, we are fortunate to have reached our target raise and to have done so with strategic investors, including our long-term shareholders and new strategic partner, Tasly,” Azadian said. 

The investment from a global pharmaceutical company validates Avicanna’s pharmaceutical approach to the cannabis business, he said. 

The company operates an R&D laboratory in Toronto and cultivates cannabis in two majority-owned locations in Santa Marta, Colombia.

Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Related Articles

Cannabis Movers & Shakers: Avicanna, Halo, Blockers BlockChain, Fyllo, Pet Releaf, Indus

Peruse the latest corporate shake-ups in the cannabis industry: Avicanna, Halo Elect Directors At Annual General Meetings of Shareholders read more

Do Cannabis Investors Need To Know About The Science Behind The Plant?

“There’s a huge misconception that everything in cannabis is the same, and every company in cannabis is doing the same thing,” says Aras Azadian, CEO of Avicanna (TSX: AVCN) (OTCQX: AVCNF), a Toronto-based cannabinoid and biopharmaceutical company. read more

Precision Extraction Solutions Is On The Hunt For Capital

Precision Extraction Solutions is hoping to raise at least $10 million in venture capital.  That's according to the Troy, Michigan-based company's founder and CTO Nick Tennant. read more

Organigram Invests In Hyasynth Biologicals, Parts Ways With Executives

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has invested an additional $2.5 million in a private biotechnology company Hyasynth Biologicals Inc. read more

Jushi Raises CA$35.5M Equity Offering

Cannabis and hemp company Jushi Holdings Inc. (CSE: JUSH) (OTCQB: JUSHF) is poised to raise CA$35.5 million through an overnight marketed offering. read more